Inhibition of four-and-a-half LIM domain protein-2 increases survival, migratory capacity, and paracrine function of human early outgrowth cells through activation of the sphingosine kinase-1 pathway: Implications for endothelial regeneration

Circulation Research

Volumn 114, Issue 1, 2014, Pages 114-123

  Ebrahimian, Talin ^a   Arfa, Omar ^a   Simeone, Stefania ^a   Lemarié, Catherine A ^a   Lehoux, Stéphanie ^a   Wassmann, Sven ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

apoptosis; endothelium; physiology; signal transduction; stem cells

Indexed keywords

2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; ACETYL LOW DENSITY LIPOPROTEIN; ALPHAVBETA5 INTEGRIN; CASPASE 3; CD18 ANTIGEN; CORTACTIN; FOUR AND A HALF LIM DOMAIN PROTEIN 2; LIM PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; MIDDLE AGED; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; YOUNG ADULT;

EID: 84892947507     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.301954     Document Type: Article

References (54)

1. Ross R. Atherosclerosis-an infammatory disease. N Engl J Med. 1999;340:115-126.
2. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85:221-228.
3. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003;25:17-24.
4. Werner N, Priller J, Laufs U, Endres M, Böhm M, Dirnagl U, Nickenig G. Bone marrow-derived progenitor cells modulate vascular reendothe-lialization and neointimal formation: effect of 3-hydroxy-3-methylgl-utaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002;22:1567-1572.
5. Werner N, Nickenig G. Endothelial progenitor cells in health and atherosclerotic disease. Ann Med. 2007;39:82-90.
6. Wassmann S, Werner N, Czech T, Nickenig G. Improvement of endothe-lial function by systemic transfusion of vascular progenitor cells. Circ Res. 2006;99:e74-e83.
7. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003;108:457-463.
8. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007.
9. Johannessen M, Møller S, Hansen T, Moens U, Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci. 2006;63:268-284.
10. Bach I. The LIM domain: regulation by association. Mech Dev. 2000;91:5-17.
11. Kadrmas JL, Beckerle MC. The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol. 2004;5:920-931.
12. Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, Ishii S, Stavnezer E, Campisi J, Fisher DE, Ben-Ze'ev A, Medrano EE. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res. 2003;63:6626-6634.
13. Morlon A, Sassone-Corsi P. The LIM-only protein FHL2 is a serum-in-ducible transcriptional coactivator of AP-1. Proc Natl Acad Sci USA. 2003;100:3977-3982.
14. Müller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schüle R. FHL2, a novel tissue-specifc co-activator of the androgen receptor. EMBO J. 2000;19:359-369.
15. Purcell NH, Darwis D, Bueno OF, Müller JM, Schüle R, Molkentin JD. Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol. 2004;24:1081-1095.
16. Samson T, Smyth N, Janetzky S, Wendler O, Müller JM, Schüle R, von der Mark H, von der Mark K, Wixler V. The LIM-only proteins FHL2 and FHL3 interact with alpha-and beta-subunits of the muscle alpha7beta1 integrin receptor. J Biol Chem. 2004;279:28641-28652.
17. Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA. Identifcation of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem. 2003;278:5188-5194.
18. Chan KK, Tsui SK, Lee SM, Luk SC, Liew CC, Fung KP, Waye MM, Lee CY. Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene. 1998;210:345-350.
19. Lange S, Auerbach D, McLoughlin P, Perriard E, Schäfer BW, Perriard JC, Ehler E. Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci. 2002;115:4925-4936.
20. Morgan MJ, Madgwick AJ. Slim defnes a novel family of LIM-proteins expressed in skeletal muscle. Biochem Biophys Res Commun. 1996;225:632-638.
21. Chu PH, Yeh LK, Lin HC, Jung SM, Ma DH, Wang IJ, Wu HH, Shiu TF, Chen J. Deletion of the FHL2 gene attenuating neovascularization after corneal injury. Invest Ophthalmol Vis Sci. 2008;49:5314-5318.
22. Chu PH, Yeh HI, Wu HH, Hong RC, Shiu TF, Yang CM. Deletion of the FHL2 gene attenuates the formation of atherosclerotic lesions after a cholesterol-enriched diet. Life Sci. 2010;86:365-371.
23. Hayashi H, Nakagami H, Takami Y, Koriyama H, Mori M, Tamai K, Sun J, Nagao K, Morishita R, Kaneda Y. FHL-2 suppresses VEGF-induced phos-phatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1. Arterioscler Thromb Vasc Biol. 2009;29:909-914.
24. Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phos-phate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem. 2002;277:35257-35262.
25. Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, Wattenberg BW, Vadas MA. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med. 2005;201:49-54.
26. Sun J, Yan G, Ren A, You B, Liao JK. FHL2/SLIM3 decreases cardio-myocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res. 2006;99:468-476.
27. Neuman NA, Ma S, Schnitzler GR, Zhu Y, Lagna G, Hata A. The four-and-a-half LIM domain protein 2 regulates vascular smooth muscle phenotype and vascular tone. J Biol Chem. 2009;284:13202-13212.
28. Endtmann C, Ebrahimian T, Czech T, Arfa O, Laufs U, Fritz M, Wassmann K, Werner N, Petoumenos V, Nickenig G, Wassmann S. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension. 2011;58:394-403.
29. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008;28:1584-1595.
30. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schäfer BW. DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol. 2000;151:495-506.
31. Stilo R, Leonardi A, Formisano L, Di Jeso B, Vito P, Liguoro D. TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation. FEBS Lett. 2002;521:165-169.
32. Martin BT, Kleiber K, Wixler V, Raab M, Zimmer B, Kaufmann M, Strebhardt K. FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle. 2007;6:1779-1788.
33. Kong Y, Shelton JM, Rothermel B, Li X, Richardson JA, Bassel-Duby R, Williams RS. Cardiac-specifc LIM protein FHL2 modifes the hypertrophic response to beta-adrenergic stimulation. Circulation. 2001;103:2731-2738.
34. König K, Diehl L, Rommerscheidt-Fuss U, Golletz C, Quast T, Kahl P, Kolanus W, Knolle P, Buettner R, Heukamp LC. Four-and-a-half LIM domain protein 2 is a novel regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic cell migration. J Immunol. 2010;185:1466-1475.
35. Slepian MJ, Massia SP, Dehdashti B, Fritz A, Whitesell L. Beta3-integrins rather than beta1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation. 1998;97:1818-1827.
36. Leifheit-Nestler M, Conrad G, Heida NM, Limbourg A, Limbourg FP, Seidler T, Schroeter MR, Hasenfuss G, Konstantinides S, Schäfer K. Overexpression of integrin beta 5 enhances the paracrine properties of circulating angiogenic cells via Src kinase-mediated activation of STAT3. Arterioscler Thromb Vasc Biol. 2010;30:1398-1406.
37. Mikelis C, Sfaelou E, Koutsioumpa M, Kieffer N, Papadimitriou E. Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotro-phin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. FASEB J. 2009;23:1459-1469.
38. Spiegel S, Milstien S. Functions of a new family of sphingosine-1- phosphate receptors. Biochim Biophys Acta. 2000;1484:107-116.
39. Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA, Gamble JR. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood. 2005;105:3169-3177.
40. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, Spyridopoulos I, Chun J, Brinkmann V, Keul P, Levkau B, Zeiher AM, Dimmeler S, Haendeler J. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol. 2007;27:275-282.
41. Schwalm S, Pfeilschifter J, Huwiler A. Sphingosine kinase 1 is critically involved in nitric oxide-mediated human endothelial cell migration and tube formation. Br J Pharmacol. 2010;160:1641-1651.
42. Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, Levade T, Moreau-Gachelin F. Overexpression of sphingosine ki-nase 1 is an oncogenic event in erythroleukemic progression. Blood. 2005;106:1808-1816.
43. Song L, Xiong H, Li J, Liao W, Wang L, Wu J, Li M. Sphingosine ki-nase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin Cancer Res. 2011;17:1839-1849.
44. Wong RC, Tellis I, Jamshidi P, Pera M, Pébay A. Anti-apoptotic effect of sphingosine-1-phosphate and platelet-derived growth factor in human embryonic stem cells. Stem Cells Dev. 2007;16:989-1001.
45. Kimura T, Boehmler AM, Seitz G, Kuçi S, Wiesner T, Brinkmann V, Kanz L, Möhle R. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. Blood. 2004;103:4478-4486.
46. Li Y, Uruno T, Haudenschild C, Dudek SM, Garcia JG, Zhan X. Interaction of cortactin and Arp2/3 complex is required for sphingosine-1-phosphate-induced endothelial cell remodeling. Exp Cell Res. 2004;298:107-121.
47. Head JA, Jiang D, Li M, Zorn LJ, Schaefer EM, Parsons JT, Weed SA. Cortactin tyrosine phosphorylation requires Rac1 activity and association with the cortical actin cytoskeleton. Mol Biol Cell. 2003;14:3216-3229.
48. Zheng Q, Zhao Y. The diverse biofunctions of LIM domain proteins: determined by subcellular localization and protein-protein interaction. Biol Cell. 2007;99:489-502.
49. Lee MJ, Thangada S, Paik JH, Sapkota GP, Ancellin N, Chae SS, Wu M, Morales-Ruiz M, Sessa WC, Alessi DR, Hla T. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell. 2001;8:693-704.
50. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005;39:733-742.
51. Pula G, Mayr U, Evans C, Prokopi M, Vara DS, Yin X, Astroulakis Z, Xiao Q, Hill J, Xu Q, Mayr M. Proteomics identifes thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. Circ Res. 2009;104:32-40.
52. Yang Z, von Ballmoos MW, Faessler D, Voelzmann J, Ortmann J, Diehm N, Kalka-Moll W, Baumgartner I, Di Santo S, Kalka C. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells. Atherosclerosis. 2010;211:103-109.
53. 3 and Smad-signalling. Cytoskeleton (Hoboken). 2010;67:773-783.
54. Ozaki H, Hla T, Lee MJ. Sphingosine-1-phosphate signaling in endothelial activation. J Atheroscler Thromb. 2003;10:125-131.